NO983452L - Procedures for Inhibiting Musculoaponeurotic Fibromatosis (Desmoid Tumors) - Google Patents

Procedures for Inhibiting Musculoaponeurotic Fibromatosis (Desmoid Tumors)

Info

Publication number
NO983452L
NO983452L NO983452A NO983452A NO983452L NO 983452 L NO983452 L NO 983452L NO 983452 A NO983452 A NO 983452A NO 983452 A NO983452 A NO 983452A NO 983452 L NO983452 L NO 983452L
Authority
NO
Norway
Prior art keywords
procedures
inhibiting
desmoid tumors
fibromatosis
inhibiting musculoaponeurotic
Prior art date
Application number
NO983452A
Other languages
Norwegian (no)
Other versions
NO983452D0 (en
Inventor
Maria L Brandi
Francesco Tonelli
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9603148.9A external-priority patent/GB9603148D0/en
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO983452L publication Critical patent/NO983452L/en
Publication of NO983452D0 publication Critical patent/NO983452D0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrrole Compounds (AREA)

Abstract

Fremgangsmåte for å hemme muskuloaponeurotiske fibromateoser omfatter administre- ring til et pattetdyr som har behov for dette av en effektiv mengde av en forbindelse med formel (I), hvor R1 og R3 uavhengig av hverandre er hydrogen, -CH3, (a) eller (b), der Ar eventuelt er substituert fenyl; R2 blir valgt fra gruppen bestående av pyrrolidin, heksame- tylenimin, og piperidin; eller et farmasøytisk akseptabelt salt eller solvat derav.Methods for inhibiting musculoaponeurotic fibromateoses include administration to a mammal in need thereof of an effective amount of a compound of formula (I), wherein R 1 and R 3 are independently hydrogen, -CH 3, (a) or (b). ) wherein Ar is optionally substituted phenyl; R 2 is selected from the group consisting of pyrrolidine, hexamethylenimine, and piperidine; or a pharmaceutically acceptable salt or solvate thereof.

NO983452A 1996-01-29 1998-07-27 Procedures for Inhibiting Musculoaponeurotic Fibromatosis (Desmoid Tumors) NO983452D0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1077396P 1996-01-29 1996-01-29
GBGB9603148.9A GB9603148D0 (en) 1996-02-15 1996-02-15 Methods of inhibiting musculoaponeurotic fibromatoses (desmoid tumors)
PCT/US1997/002287 WO1997026878A1 (en) 1996-01-29 1997-01-27 Methods of inhibiting musculoaponeurotic fibromatoses (desmoid tumors)

Publications (2)

Publication Number Publication Date
NO983452L true NO983452L (en) 1998-07-27
NO983452D0 NO983452D0 (en) 1998-07-27

Family

ID=26308707

Family Applications (1)

Application Number Title Priority Date Filing Date
NO983452A NO983452D0 (en) 1996-01-29 1998-07-27 Procedures for Inhibiting Musculoaponeurotic Fibromatosis (Desmoid Tumors)

Country Status (11)

Country Link
EP (1) EP0907361A4 (en)
JP (1) JP2000503995A (en)
KR (1) KR19990082055A (en)
CN (1) CN1209746A (en)
AU (1) AU707675B2 (en)
CZ (1) CZ235398A3 (en)
EA (1) EA199800678A1 (en)
IL (1) IL125523A0 (en)
NO (1) NO983452D0 (en)
PL (1) PL328127A1 (en)
WO (1) WO1997026878A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2135195C1 (en) * 1998-12-17 1999-08-27 Овсюк Валерий Григорьевич Method for producing material containing prostate cells and treating the cases of uterine fibromatosis, chronic prostatitis and male sexual function disorders by applying transplantation method
AU781168B2 (en) * 2001-01-26 2005-05-12 Pfizer Products Inc. Method of treating certain cancers using an estrogen agonist/antagonist

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW366342B (en) * 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
US5552162A (en) * 1993-02-09 1996-09-03 Arch Development Corporation Method for improvement of scar size and appearance
US5457116A (en) * 1993-10-15 1995-10-10 Eli Lilly And Company Methods of inhibiting uterine fibrosis
IL111287A0 (en) * 1993-10-15 1994-12-29 Lilly Co Eli Methods for treating resistant neoplasms
US5574047A (en) * 1993-12-21 1996-11-12 Eli Lilly And Company Methods of inhibiting imperfect tissue repair

Also Published As

Publication number Publication date
PL328127A1 (en) 1999-01-18
KR19990082055A (en) 1999-11-15
JP2000503995A (en) 2000-04-04
EP0907361A4 (en) 2002-05-02
IL125523A0 (en) 1999-03-12
AU2124097A (en) 1997-08-20
NO983452D0 (en) 1998-07-27
AU707675B2 (en) 1999-07-15
WO1997026878A1 (en) 1997-07-31
CZ235398A3 (en) 1999-02-17
EA199800678A1 (en) 1999-02-25
CN1209746A (en) 1999-03-03
EP0907361A1 (en) 1999-04-14

Similar Documents

Publication Publication Date Title
NO973635L (en) Method of inhibiting cell-cell adhesion
NO971520L (en) Method of inhibiting conditions associated with neuropeptide Y
NO944911L (en) Non-peptide takykininreseptorantagonister
RU94045846A (en) Use of benzothiophene derivatives for thrombin inhibition
NO990671L (en) Muscarin antagonistic ethers
NO944927L (en) Method for inhibiting pulmonary hypertensive disease
DK0651999T3 (en) Methods for inhibiting uterine fibrosis
DK0659417T3 (en) Methods for inhibiting dysfunctional uterine bleeding
NO944914L (en) Method of inhibiting autoimmune diseases
MX9701325A (en) Methods of inhibiting ulcerative mucositis.
MX9701360A (en) Methods of inhibiting demyelinating and dysmyelinating diseases.
NO944926L (en) Methods for Inhibiting Myeloperoxidase Activity
UA32427C2 (en) The use of benzothiophene or pharmaceutical acceptable salts or solvate thereof for inhibition of angiogenesis and/or angiogenic diseases
NO944924L (en) Procedures for inhibiting Turner's syndrome
NO944933L (en) Procedure for inhibiting disease states of the breast
NO975580L (en) Method of inhibiting melanoma
NO970786L (en) Procedure for inhibiting bone degradation
NO944931L (en) Use of 2-phenyl-3-aroylbenzothiophenes for inhibiting early sexual maturity
NO981578L (en) Method of inhibiting plasminogen activator inhibitor I
NO973367L (en) Method of inhibiting environmental estrogen
NO983452L (en) Procedures for Inhibiting Musculoaponeurotic Fibromatosis (Desmoid Tumors)
NO973609L (en) Method of inhibiting the effects of IL-6
NO20000750L (en) Procedure for reducing platelet counts
NO970783L (en) Procedure for preventing endometrial cancer
NO971029L (en) Methods for inhibiting endometrial metoses

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application